KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Consolidated Net Income (2016 - 2025)

Pfizer (PFE) has disclosed Consolidated Net Income for 17 consecutive years, with $25.0 million as the latest value for Q2 2025.

  • On a quarterly basis, Consolidated Net Income rose 47.06% to $25.0 million in Q2 2025 year-over-year; TTM through Dec 2025 was $25.0 million, a 127.27% increase, with the full-year FY2025 number at $25.0 million, up 127.27% from a year prior.
  • Consolidated Net Income was $25.0 million for Q2 2025 at Pfizer, up from $7.0 million in the prior quarter.
  • In the past five years, Consolidated Net Income ranged from a high of $35.0 million in Q3 2022 to a low of -$248.0 million in Q4 2021.
  • A 5-year average of -$30.5 million and a median of -$2.0 million in 2023 define the central range for Consolidated Net Income.
  • Peak YoY movement for Consolidated Net Income: plummeted 1000.0% in 2022, then soared 950.0% in 2024.
  • Pfizer's Consolidated Net Income stood at -$248.0 million in 2021, then skyrocketed by 91.53% to -$21.0 million in 2022, then dropped by 23.81% to -$26.0 million in 2023, then skyrocketed by 126.92% to $7.0 million in 2024, then soared by 257.14% to $25.0 million in 2025.
  • Per Business Quant, the three most recent readings for PFE's Consolidated Net Income are $25.0 million (Q2 2025), $7.0 million (Q4 2024), and -$8.0 million (Q3 2024).